论文部分内容阅读
目的比较直接测序法和实时聚合酶链反应-高分辨率融解曲线技术(qPCR-HRM)检测非小细胞肺癌(NSCLC)表皮生长因子受体(EGFR)基因突变的差异,探讨适用于临床的EGFR基因突变检测方法。方法 52例NSCLC患者外周血中EGFR突变采用qPCR-HRM法,其组织标本中EGFR突变采用直接测序法,采用卡方检验比较检测结果。结果 qPCR-HRM法检测外周血中EGFR突变率为34.6%(18/52),直接测序法检测的组织标本中突变率为30.8%(16/52),结果差异无统计学意义(χ2=0.17,P>0.05);2种方法的总符合率为96.2%(50/52)。结论与直接测序法相比,qPCR-HRM法检测NSCLC患者外周血中EGFR突变更适用于临床筛选适合EGFR酪氨酸激酶抑制剂(EGFR-TKI)治疗的NSCLC患者。
Objective To compare the difference of epidermal growth factor receptor (EGFR) gene mutation in non-small cell lung cancer (NSCLC) between direct sequencing and real-time polymerase chain reaction-high resolution melting curve technique (qPCR-HRM) Gene mutation detection method. Methods 52 cases of NSCLC patients with peripheral blood EGFR mutation using qPCR-HRM method, the EGFR mutation in tissue samples using direct sequencing, chi-square test to compare the test results. Results The rate of EGFR mutation in peripheral blood was 34.6% (18/52) by qPCR-HRM method. The mutation rate was 30.8% (16/52) in the tissue samples detected by direct sequencing, the difference was not statistically significant (χ2 = 0.17 , P> 0.05). The total coincidence rate of the two methods was 96.2% (50/52). Conclusion Compared with direct sequencing, qPCR-HRM is more suitable for clinical screening of NSCLC patients with EGFR tyrosine kinase inhibitor (EGFR-TKI) for the detection of EGFR mutation in peripheral blood of NSCLC patients.